BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20210101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220823
DTEND;VALUE=DATE:20220826
DTSTAMP:20260516T023959
CREATED:20220526T184543Z
LAST-MODIFIED:20220526T184543Z
UID:34247-1661212800-1661471999@www.pharmajournalist.com
SUMMARY:Cell Therapy Analytical Development Summit Europe
DESCRIPTION:Cell Therapy Analytical Development Summit Europe\, taking place from 23-25 of August in London\, will bring together professionals working in CMC\, QC\, process development\, and regulatory functions. \nJoin your peers in person to: \n\nLearn to develop a successful potency assay to determine product activity\nExplore reference standards for state-of-the-art analytical development\nDiscover new technology to expand and improve your analytical toolbox\nDevelop and validate analytical methods to fulfil GMP guidelines\nStreamline final product characterisation by starting with the end in mind\n\nYou can view the event guide here: https://ter.li/nxuxfd \nSecure your place at the summit here: https://ter.li/551w6c \nWe are looking forward to welcoming you to London this August!
URL:https://www.pharmajournalist.com/event/cell-therapy-analytical-development-summit-europe/
LOCATION:Hilton London Paddington\, 146 Praed St\, London\, W2 1EE\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220829
DTEND;VALUE=DATE:20220902
DTSTAMP:20260516T023959
CREATED:20220527T124300Z
LAST-MODIFIED:20220527T124300Z
UID:34298-1661731200-1662076799@www.pharmajournalist.com
SUMMARY:6th IPF Summit
DESCRIPTION:With two approved therapeutics and the field working to develop the next generation of IPF drugs\, the opportunity to become the undisputed\, most effective\, and disease-modifying agent on the market has never been greater. \nFrom repairing and regenerating lung tissue to illuminating innovative clinical trial design and advance scientific progress; the 6th IPF Summit is your one-stop-shop to supercharge IPF research and drug development. \nWhat’s new and unmissable for 2022: \n\n29 brand new industry speakers\, as well as returning KOLs including Fernando Martinez\, Naftali Kaminski\, Toby Maher\, and many more\n6 interactive workshops to delve into IPF’s hottest topics\, discuss challenges\, pose your burning questions to leading experts\, and highlight the respiratory pipeline development opportunities including SSc-ILD\, COPD\, and COVID fibrosis\nA brand-new Tissue Repair and Regeneration Day\, with dedicated sessions on halting and reversing disease progression to rethinking senescence to unlocking cell therapies. Get more insight than ever before on evolving basic science and regenerative therapy opportunities\nExclusive presentations on the regulatory and patient perspectives to inform clinical trial design and future therapeutic development\n\nGet in the room with your team to meet peers and KOLs and take away critical insights at the world’s most comprehensive and dedicated IPF conference. Confirmed attendees include AbbVie\, Boehringer Ingelheim\, Bayer\, BMS\, Genentech\, Galecto\, Novartis\, and Trevi Therapeutics. \nFrom navigating pathophysiology and pathobiology\, exploring all available target opportunities to leveraging synthetic control arms in clinical trials; this is a conversation you won’t want to miss to transform your IPF research. \nTo know more visit: https://ter.li/6yo2nd
URL:https://www.pharmajournalist.com/event/6th-ipf-summit/
LOCATION:Westin Boston Seaport District\, 425 Summer St\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220830
DTEND;VALUE=DATE:20220902
DTSTAMP:20260516T023959
CREATED:20220526T182710Z
LAST-MODIFIED:20220526T182710Z
UID:34236-1661817600-1662076799@www.pharmajournalist.com
SUMMARY:2nd Integrin-Targeted Drug Development Summit
DESCRIPTION:Over the last 12 months\, the industry has witnessed promising data and candidates entering the clinic. 7 Hills Pharma\, Corbus Pharmaceuticals\, Vincerx\, and Morphic are paving the way to develop a safe\, efficacious integrins-targeted drug to modify disease biology\, which will be a game-changer for diseases such as oncology\, autoimmune\, and ophthalmology\, with unmet medical needs. \nIn collaboration with leading integrin drug developers\, including Genentech\, 7 Hills Pharma\, and Pfizer\, the 2nd Integrin-Targeted Drug Development Summit is designed for industry leaders to unite and outline clinical strategies for success\, including patient selection biomarkers and dosing. \nGet your critical questions answered to supercharge your clinical programs\, direct your drug pipelines and ensure you take lessons learned to successfully modulate integrins to improve treatment regimens in chronic\, familiar\, and rare diseases.  \nJoin us for this 3-day summit to gain unparalleled insights and experience first-hand from integrin drug developers to accelerate your candidate into the clinic and develop a first-in-class treatment option by modifying underlying disease biology for our patients. \nTo know more visit: https://ter.li/qoq74v
URL:https://www.pharmajournalist.com/event/2nd-integrin-targeted-drug-development-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR